


1FW



Date of Deposit: March 28, 2005

Attorney Docket No. VPI/02-143 US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Whitney, et al.
CONFIRMATION No.: 8813
SERIAL NUMBER: 10/656,029 EXAMINER: Not Yet Assigned
FILING DATE: September 5, 2003
GROUP ART UNIT: 1636
FOR: METHODS AND COMPOSITIONS FOR RAPID DEVELOPMENT OF SCREENING ASSAYS

March 28, 2005
Cambridge, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.
- ☒ Copy(ies) of references Citation No(s). **B1-B3, C1-C3** is/are attached.
 - ☐ Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.)
 - ☒ A copy of the International Search Report received in the corresponding PCT Application No. **PCT/US 03/28078** is attached herewith.
- (b) ☒ No fee is believed due because:
- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
 - ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
 - ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
 - ☒ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

APPLICANTS: Whitney, et al.
U.S.S.N.: 10/656,029


- (c) ☐ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

APPLICANTS: Whitney, et al.
U.S.S.N.: 10/656,029



The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,




Nandakumar Govindaswamy
Reg. No. 56,285
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6619/6100
Fax: (617) 444-6483

CERTIFICATE OF MAILING

**I hereby certify that this correspondence is being deposited
with the United States Postal Service as first class mail in
an envelope addressed to: Commissioner For Patents,
P.O. Box 1450, Alexandria, VA 22313-1450**

on March 28, 2005
Susan Betty -Hunn



Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number	10/656,029
Filing Date	September 5, 2003
First Named Inventor	Michael Allen Whitney
Group Art Unit	1636
Examiner Name	Not Yet Assigned
Attorney Docket Number	VPI/02-143 US2

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	EP 1 199 371	Rohm and Haas Company	24 April 2002	X
	B2	WO 02/059303	Ludwig Institute For Cancer Research	1 August 2002	X
	B3	EP 1 371 662	Lion Bioscience Ag.	17 December 2003	X

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Takahashi, et al., "Dual Action of Isoprenols From Herbal Medicines on Both PPAR γ and PPAR α in 3T3-L1 Adipocytes and HepG2 Hepatocytes" Febs. Letters, Elsevier Science Pub., Vol. 514, No. 2-3, Pages 315-322, 2002.
	C2	Lehmann, et al., "An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPAR γ)" J. of Biological Chem., Vol. 270, No. 22, Pages 12953-12956, 1995.
	C3	Sampson, et al., Identification and Characterization of Androgen Receptor Associated Coregulators in Prostate Cancer Cells" J. of Biological Regulators and Homeostatic Agents, Vol. 15, No. 2, Pages 123-129, 2001.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.